#ESMO25: Positive phase III #ClinicalTrial data with T-DXd in high-risk, HER2+ #EarlyBreastCancer suggest that a paradigm change in the treatment of these patients may be imminent.
Read more in the #ESMODailyReporter 📌 https://ow.ly/n1y050Xeuz0

#BreastCancer #ADC

Test Banner

🔗 Read more: bit.ly/ONCOnews17O-2

#ONCOnews #OncoAlert #OncEd #EarlyBreastCancer #OncologyResearch #PatientCare #ClinicalTrialResults #ESMO2025

Join us for a virtual treatment expert panel with a focus on #EarlyBreastCancer. This event is part of the #BreastCancerInYoungAdults forum series for patients, survivors, and loved ones.
🗓️Wed, Sept 10 | 6:30 – 7:45 pm ET
Register Today: dfci.zoom.us/webinar/regi...

Study Supports Tamoxifen for DCIS Early Breast Cancers - Drugs.com MedNews The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast cancer, a

New study: Tamoxifen cuts breast cancer recurrence risk by 44-51% in early DCIS cases. Women who took the hormone therapy after lumpectomy saw a significant reduction in cancer returning, per research at the San Antonio Breast Cancer Symposium. #EarlyBreastCancer

On the other side of research this time. Doing my bit for research. #EarlyBreastCancer #NHSGrampian